Yao Tzy-Jyun, Zhang Joel, Malee Kathleen, Smith Renee, Rice Mabel L, Redmond Sean M, Williams Paige L
Center for Biostatistics in AIDS Research, Harvard T. H. Chan School of Public Health, Boston, MA.
Psychiatry and Behavioral Science, Northwestern University Feinberg School of Medicine, Chicago, IL.
J Acquir Immune Defic Syndr. 2025 Oct 1;100(2):131-136. doi: 10.1097/QAI.0000000000003720.
Atazanavir (ATV) has been a preferred protease inhibitor prescribed to pregnant women with HIV, often given with tenofovir disoproxil fumarate (TDF)/emtricitabine. Studies have reported associations of prenatal exposure to ATV with early neurodevelopmental problems among children HIV exposed but uninfected (CHEU).
Prospective US-based multisite cohort study of CHEU.
Monolingual English-speaking CHEU from the Surveillance Monitoring for ART Toxicities study were evaluated for cognition, language, and behavior at age 5 years. Exploratory factor analyses using 10 composite scores were performed to estimate underlying factors reflecting covariation of these domains. Mean differences of standardized factor scores were compared between CHEU exposed to TDF/emtricitabine with/without ATV versus zidovudine/lamivudine without ATV using linear generalized estimating equations, adjusting for confounders and accounting for clustering by site. Separate analyses were conducted by timing of maternal ART initiation (preconception versus postconception).
In total, 585 CHEU were exposed to TDF/emtricitabine with/without ATV, or zidovudine/lamivudine without ATV, and had valid composite scores. Two factors were identified, explaining 27%-88% variability of individual composite scores. Factor 1 contributed to cognitive and language domains, Factor 2 contributed to the behavioral domain. Differences in factor scores among ART exposure groups were not observed for cognition/language, but CHEU exposed to TDF/emtricitabine with/without ATV had worse behavioral functioning factor scores compared with zidovudine/lamivudine without ATV in the postconception strata, especially for those exposed to TDF/emtricitabine/ATV when ARVs were initiated in trimester 1.
Prenatal exposure to TDF/emtricitabine/atazanavir was associated with factor scores reflecting parent-reported behavioral concerns among CHEU whose mothers initiated ARVs during pregnancy.
阿扎那韦(ATV)一直是为感染HIV的孕妇开具的首选蛋白酶抑制剂,通常与替诺福韦酯(TDF)/恩曲他滨联合使用。研究报告称,在未感染HIV但暴露于HIV的儿童(CHEU)中,产前暴露于ATV与早期神经发育问题有关。
基于美国的CHEU前瞻性多中心队列研究。
对来自抗逆转录病毒治疗毒性监测研究的只会说英语的CHEU在5岁时进行认知、语言和行为评估。使用10个综合评分进行探索性因素分析,以估计反映这些领域协变的潜在因素。使用线性广义估计方程比较暴露于含或不含ATV的TDF/恩曲他滨的CHEU与不含ATV的齐多夫定/拉米夫定的标准化因素评分的平均差异,并对混杂因素进行调整,并按地点进行聚类分析。根据孕产妇抗逆转录病毒治疗开始时间(受孕前与受孕后)进行单独分析。
共有585名CHEU暴露于含或不含ATV的TDF/恩曲他滨,或不含ATV的齐多夫定/拉米夫定,并具有有效的综合评分。确定了两个因素,解释了个体综合评分27%-88%的变异性。因素1影响认知和语言领域,因素2影响行为领域。在认知/语言方面,未观察到抗逆转录病毒治疗暴露组之间的因素评分差异,但在受孕后分层中,暴露于含或不含ATV的TDF/恩曲他滨的CHEU与不含ATV的齐多夫定/拉米夫定相比,行为功能因素评分更差,尤其是那些在孕早期开始接受抗逆转录病毒药物治疗时暴露于TDF/恩曲他滨/ATV的儿童。
产前暴露于TDF/恩曲他滨/阿扎那韦与反映其母亲在孕期开始接受抗逆转录病毒治疗的CHEU中家长报告的行为问题的因素评分有关。